![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](http://nida.nih.gov/sites/default/files/images/valenza_zamarripa_fig1.gif)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/styles/content_image_medium/public/images/valenza_zamarripa_promo.jpg?itok=HRbtRBEw)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
![Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. - Abstract - Europe PMC Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3378255/bin/cn-2011-00128x_0006.jpg)
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. - Abstract - Europe PMC
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g003.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update](https://www.globaldata.com/store/wp-content/uploads/sites/2/2022/04/Hyperalgesia-pipeline-drugs-market-by-targets.png)
Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
![Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects | American Journal of Psychiatry Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects | American Journal of Psychiatry](https://ajp.psychiatryonline.org/cms/10.1176/ajp.155.4.470/asset/images/medium/a95f2.jpeg)
Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects | American Journal of Psychiatry
![Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging | ACS Chemical Neuroscience Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging | ACS Chemical Neuroscience](https://pubs.acs.org/cms/10.1021/acschemneuro.8b00293/asset/images/large/cn-2018-00293f_0001.jpeg)
Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging | ACS Chemical Neuroscience
![La FDA degli Stati Uniti approva l'innovativo agonista periferico del recettore oppioide Kappa (KOR) Korsuva! - Notizie del settore - Notizie - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd La FDA degli Stati Uniti approva l'innovativo agonista periferico del recettore oppioide Kappa (KOR) Korsuva! - Notizie del settore - Notizie - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd](http://it.hspchem.com/Content/uploads/2021524038/20210913162501ac357b6b0aa241a087558b2827205601.jpg)
La FDA degli Stati Uniti approva l'innovativo agonista periferico del recettore oppioide Kappa (KOR) Korsuva! - Notizie del settore - Notizie - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors | Journal of Medicinal
![Kappa-opioid receptor agonist U50448H protects against renal ischemia-reperfusion injury in rats via activating the PI3K/Akt signaling pathway | Acta Pharmacologica Sinica Kappa-opioid receptor agonist U50448H protects against renal ischemia-reperfusion injury in rats via activating the PI3K/Akt signaling pathway | Acta Pharmacologica Sinica](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Faps.2017.51/MediaObjects/41401_2018_Article_BFaps201751_Fig1_HTML.jpg)
Kappa-opioid receptor agonist U50448H protects against renal ischemia-reperfusion injury in rats via activating the PI3K/Akt signaling pathway | Acta Pharmacologica Sinica
Kappa Agonist-Induced Diuresis: Evidence for Stereoselectivity, Strain Differences, Independence of Hydration Variables and a Re
![Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink](https://media.springernature.com/lw685/springer-static/image/chp%3A10.1007%2F164_2020_431/MediaObjects/500126_1_En_431_Fig1_HTML.png)
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/asset/35d59cc9-5e24-4990-b0eb-4fc248e3274c/9_ra117_f1.gif)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g001.jpg)